(SCYX) SCYNEXIS, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SCYX) SCYNEXIS, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This SCYNEXIS, Inc. 4P's Marketing Mix Analysis shows what the product is, how it’s used, and how SCYNEXIS positions, prices, distributes, and promotes it; the page contains a real preview/sample of the actual analysis so you can assess style and substance before buying—purchase the full version to get the complete, ready-to-use report.
Product
BREXAFEMME
BREXAFEMME is SCYNEXIS, Inc.'s flagship product and contains ibrexafungerp tablets. It is FDA-approved in the U.S. for vulvovaginal candidiasis, giving SCYNEXIS a differentiated oral antifungal in a market where about 75% of women face VVC at least once. Its product position is built on a prescription-only, branded therapy with clear clinical use.
Oral ibrexafungerp
Oral ibrexafungerp is SCYNEXIS’s lead antifungal asset, with FDA approval in 2021 for acute vulvovaginal candidiasis and recurrent VVC suppression. Oral dosing supports outpatient use and easier adherence than IV therapy. The oral tablet label uses 300 mg twice on day 1 for treatment, a practical fit for clinic and retail care.
IV ibrexafungerp
IV ibrexafungerp adds a second route to SCYNEXIS, Inc.’s antifungal platform, moving the asset beyond oral use. That matters because IV dosing can reach hospitalized patients with serious fungal infections, widening the addressable market and supporting a broader life-cycle strategy for the same molecule.
Broad fungal indications
SCYNEXIS, Inc.'s broad fungal portfolio spans recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections, so it covers both common and life-threatening disease. This matters because invasive fungal infections still have limited treatment options and high clinical need, which supports value across outpatient and hospital use.
- Targets common and invasive disease
- Addresses limited-treatment gaps
- Supports hospital and outpatient demand
Phase 3 CANDLE
Phase 3 CANDLE adds clinical depth to SCYNEXIS, Inc.’s ibrexafungerp by completing a late-stage study in prevention of recurrent VVC, a market with high repeat-burden. In 2025, SCYNEXIS, Inc. reported $0.0 million product revenue and a net loss of $42.9 million, so Phase 3 progress matters for value support. Completion also lowers development risk and strengthens the product story.
- Phase 3 CANDLE completed
- Targets recurrent VVC prevention
- Supports late-stage product profile
SCYNEXIS Faces Losses as BREXAFEMME Awaits Phase 3 Breakthrough
SCYNEXIS, Inc.’s Product mix is centered on BREXAFEMME (ibrexafungerp), an FDA-approved oral antifungal for VVC and recurrent VVC suppression. The 2025 product line had $0.0 million revenue, while the company posted a $42.9 million net loss, so product value still depends on late-stage execution like Phase 3 CANDLE.
| Item | 2025 |
|---|---|
| Product revenue | $0.0M |
| Net loss | $42.9M |
| Lead product | BREXAFEMME |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of SCYNEXIS, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Distills SCYNEXIS’s 4Ps into a quick, decision-ready snapshot that saves time and supports clear strategic discussion.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to validate assumptions and speed investor due diligence.
Place
Jersey City HQ
SCYNEXIS, Inc. is headquartered in Jersey City, New Jersey, and was founded in 1999. Its U.S.-centered operations keep leadership, research, and corporate functions close to the main market. Jersey City also gives SCYNEXIS access to the New York–New Jersey biotech corridor, a dense life-sciences hub.
U.S. market
BREXAFEMME is approved in the United States, and SCYNEXIS, Inc. sells it through prescription and pharmacy fulfillment. The U.S. is the core commercial market, with the FDA reporting about 1.4 million outpatient candidiasis visits each year, supporting the addressable base. U.S. payer access and physician prescribing drive near-term revenue potential.
China partners
SCYNEXIS, Inc. has agreements with Hansoh and Jiangsu Hansoh in Shanghai, China, extending its program into Greater China. This broadens reach beyond the U.S. and taps a market of about 1.4 billion people. The China partners add local development and commercial access, which matters for scaling outside SCYNEXIS, Inc.'s home market.
Russia partner
SCYNEXIS, Inc. uses R-Pharm, CJSC as a Russia partner to extend ibrexafungerp development and access outside the U.S., which cuts the need for a large direct sales team. This partner-led model keeps fixed selling costs lower and can speed local market entry if approvals land. In 2025, SCYNEXIS still had no broad commercial footprint, so this route matters for reach.
Non-U.S. access via R-Pharm.
Lower sales force cost burden.
Supports ibrexafungerp expansion.
Specialty care channel
SCYNEXIS, Inc.’s antifungal therapies are physician-directed and prescription-only, so the specialty care channel matters more than retail shelves. Access runs through prescribers, specialty pharmacies, and hospital-linked formulary decisions, which makes adoption slower but more controlled than OTC drugs.
- Physician gatekept access
- Specialty pharmacy distribution
- Hospital-linked buying pathways
- No OTC retail channel
SCYNEXIS Stays U.S.-Focused, with Limited Global Reach
SCYNEXIS, Inc. keeps Place U.S.-led, with Jersey City as its base and BREXAFEMME sold through prescription and specialty pharmacy channels. U.S. access matters most, while Hansoh in China and R-Pharm in Russia extend reach without a large direct sales force. In 2025, SCYNEXIS, Inc. still had no broad commercial footprint.
| Place factor | Data |
|---|---|
| HQ | Jersey City, New Jersey |
| Core market | United States |
| Non-U.S. access | Hansoh, R-Pharm |
| Channel | Rx, specialty pharmacy |
What You See Is What You Get
SCYNEXIS, Inc. Reference Sources
The preview shown here is the actual SCYNEXIS, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use.
Promotion
FDA approval
FDA approval is the core promotion hook for SCYNEXIS, Inc. BREXAFEMME was approved by the U.S. FDA for vulvovaginal candidiasis in 2021, giving the brand clinical validation and a clear trust signal. As the first oral non-azole antifungal in its class, the approval helps SCYNEXIS, Inc. differentiate the molecule and support prescriber adoption.
CANDLE phase 3
SCYNEXIS, Inc.’s CANDLE Phase 3 study for ibrexafungerp was completed to test prevention of recurrent vulvovaginal candidiasis, making late-stage data a core promotional asset. Phase 3 results matter because they support claims on efficacy, safety, and label strength more than preclinical or early clinical data. For SCYNEXIS, Inc., that late-stage proof is the clearest way to build trust with prescribers and payers.
Partner announcements
Partner announcements with Merck, Hansoh, and R-Pharm expanded SCYNEXIS, Inc.'s reach and put the program in front of larger pharma audiences. The Hansoh deal was valued at up to $212 million in upfront, milestone, and royalty payments, which gave the asset clear commercial credibility. These public ties also signaled outside validation, since three named partners saw enough value to attach their brands to the program.
Medical education
SCYNEXIS, Inc.'s medical education should focus on prescribers and fungal-disease specialists, because antifungal use depends on label, resistance, and guideline awareness. For ibrexafungerp, evidence-based talks and publications matter most; it has 2 FDA-approved uses, so clear dosing and safety data drive uptake.
Scientific congresses and peer-reviewed papers are the best channels for this market. They help move awareness into trial use in a segment where treatment choices are often made by a small specialist base.
- Target: prescribers and specialists
- Use: publications and congress data
- Focus: 2 approved uses, clear evidence
Investor communications
SCYNEXIS, Inc. uses SEC filings and earnings communications to keep investors updated on pipeline progress and partnership activity. These disclosures, including 10-K, 10-Q, and 8-K reports, show development milestones, cash use, and deal updates in real time. For a public biotech, that steady flow of data helps the market track risk and value.
- SEC filings: 10-K, 10-Q, 8-K
- Shows pipeline and partner updates
- Tracks milestones and cash use
SCYNEXIS Builds Trust with FDA Wins and Partner Backing
SCYNEXIS, Inc. promotes BREXAFEMME through FDA approval, Phase 3 data, and partner validation. The 2021 FDA approval for vulvovaginal candidiasis and ibrexafungerp’s 2 FDA-approved uses give the brand clear trust signals. Public deals, including Hansoh’s up to $212 million package, add outside credibility. Medical education, congresses, and SEC filings keep the story in front of prescribers and investors.
| Promotion lever | Key fact |
|---|---|
| FDA approval | 2021 |
| Approved uses | 2 |
| Hansoh deal | Up to $212 million |
Price
150 mg tablets
BREXAFEMME is sold as 150 mg tablets, so pricing is tied to tablet strength and the prescription pack size. Its branded specialty-antifungal position supports premium pricing versus generic azoles, with access shaped by diagnosis-specific use and limited tablet counts per fill. For SCYNEXIS, Inc., this format keeps the product in a higher-value, prescription-only lane.
4-tablet carton
SCYNEXIS, Inc.'s acute VVC regimen uses 300 mg twice on day 1, so one treatment course equals 4 tablets. That makes the 4-tablet carton the right unit for pricing and dispensing. SCYNEXIS priced Brexafemme around this carton format at launch, aligning the pack with one full acute course.
24-tablet carton
The 24-tablet carton matches the recurrent VVC prevention regimen, which uses 6 monthly doses of 4 tablets each, so one pack covers the full course. That bigger pack supports longer prophylaxis use and simpler refill planning for patients and prescribers. It also fits a higher-value, adherence-focused pricing model for SCYNEXIS, Inc.
$496.50 WAC
SCYNEXIS set the wholesale acquisition cost at $496.50 for each 4-tablet carton, or about $124.13 per tablet, for the one-day vulvovaginal candidiasis course. That is a branded prescription-drug launch price, so the list price sits well above generic antifungal options and supports premium positioning in the U.S. hospital and retail channel mix.
- WAC: $496.50 per carton
- 4 tablets per course
- About $124.13 per tablet
- Branded Rx pricing model
$2,979.00 WAC
SCYNEXIS set the wholesale acquisition cost at $2,979.00 for a 24-tablet carton, which matches the 6-month recurrent vulvovaginal candidiasis prevention regimen.
That pricing frames the product as a specialty drug, where payer reimbursement and pharmacy channel economics matter more than list price alone.
- 24 tablets: $2,979.00 WAC
- 6-month prevention regimen
- Specialty-drug reimbursement fit
SCYNEXIS Prices BREXAFEMME as a Premium Oral Antifungal
SCYNEXIS, Inc. prices BREXAFEMME as a premium branded oral antifungal: $496.50 per 4-tablet acute VVC carton, or about $124.13 per tablet, and $2,979.00 per 24-tablet recurrent VVC carton. The 4-tablet pack covers one acute course, while the 24-tablet pack covers the 6-month prevention regimen. That supports specialty-drug reimbursement and higher-value dispensing.
| Pack | WAC | Use |
|---|---|---|
| 4 tablets | $496.50 | Acute VVC |
| 24 tablets | $2,979.00 | Recurrent VVC prevention |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.